Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
- UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001 October 23, 2026
Penetrium: A Breakthrough in Overcoming Cold Tumors and Metastatic Cancer
/in Preclinical Research/by MaxPioglitazone: Diabetes Drug Shows Promise for Treating Prostate Cancer
/in Drug repurposing, Preclinical Research/by MaxUPDATE: JANX007 Starts Phase 1b Expansion Studies
/in Clinical Trial, Metastatic, Phase 1/by MaxNTS071 to Target p53 Y220C Mutation in Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxA New Insight From the ARANOTE Trial for mHSPC
/in Post-hoc/by MaxSetback in Prostate Cancer Trial: CAPItello-280 Study for Truqap Discontinued
/in Clinical Trial, Metastatic, Phase 3/by MaxPrecision in Action: How Logic-Gating Redefines Targeted Therapy
/in Not PCa related/by MaxUPDATE: ATNM-400 a Promising Antibody Radioconjugate Delivering 225 Ac
/in Preclinical Research/by Max